5 Key Takeaways
-
1
The COMO and CAPRI trials evaluate Duravyu, a tyrosine kinase inhibitor, for treating diabetic macular edema (DME) patients.
-
2
Duravyu is administered every 6 months and aims to achieve similar visual outcomes as aflibercept while reducing treatment burden.
-
3
The trials include approximately 240 patients each, comparing Duravyu with aflibercept, focusing on best-corrected visual acuity and safety.
-
4
Duravyu targets multiple pathways, potentially addressing treatment resistance seen in 40-60% of DME patients with anti-VEGF therapies.
-
5
The trials aim to evaluate Duravyu's effectiveness in both previously treated and treatment-naïve DME patients to inform real-world applications.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
